How does CagriSema compare to Wegovy in diabetes trials?

CagriSema demonstrated greater reductions in body weight and blood sugar levels compared to Wegovy in a late-stage trial for type 2 diabetes patients.

What is CagriSema made of?

CagriSema is a weekly injection that combines cagrilintide, which mimics a pancreatic hormone, and semaglutide, the active ingredient in Wegovy that mimics a gut hormone.

What were the results of the CagriSema trial for type 2 diabetes?

In a trial of 2,728 patients, CagriSema helped participants lose about 14.2% of their body weight and reduced HbA1c levels by 1.91 percentage points, compared to Wegovy's results.

Home / Health / Next-Gen Diabetes Drug CagriSema Beats Wegovy in Key Trial

Next-Gen Diabetes Drug CagriSema Beats Wegovy in Key Trial

2 Feb

•

Summary

CagriSema achieved greater weight loss than Wegovy in a type 2 diabetes trial.
The new drug also demonstrated superior reduction in blood sugar levels.
CagriSema combines active ingredients from two different mimic hormones.

Next-Gen Diabetes Drug CagriSema Beats Wegovy in Key Trial

In a significant development for type 2 diabetes treatment, Novo Nordisk's next-generation drug, CagriSema, has demonstrated superior efficacy over its current blockbuster, Wegovy. A late-stage trial revealed that CagriSema, administered in a high-dose weekly injection, facilitated approximately 14.2% body weight loss in participants over 68 weeks, surpassing Wegovy's 10.2% reduction.

This experimental therapy combines cagrilintide and semaglutide, mimicking pancreatic and gut hormones, respectively. Beyond weight management, CagriSema also proved more effective in controlling blood sugar. Participants receiving CagriSema saw a 1.91 percentage point drop in HbA1c levels, compared to a 1.76 percentage point decrease with semaglutide alone. The trial involved 2,728 individuals with type 2 diabetes already on standard treatments.